Cargando…
Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (...
Autores principales: | Sun, Yige, Yang, Jie, Li, Yingbo, Luo, Jing, Sun, Jiemei, Li, Daoshuang, Wang, Yuchen, Wang, Kai, Yang, Lili, Wu, Lina, Sun, Xilin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717478/ https://www.ncbi.nlm.nih.gov/pubmed/36457016 http://dx.doi.org/10.1186/s12943-022-01681-y |
Ejemplares similares
-
c-Met-Targeting (19)F MRI Nanoparticles with Ultralong Tumor Retention for Precisely Detecting Small or Ill-Defined Colorectal Liver Metastases
por: Li, Daoshuang, et al.
Publicado: (2023) -
A phase II study of the efficacy and safety of the MET inhibitor
capmatinib (INC280) in patients with advanced hepatocellular
carcinoma
por: Qin, Shukui, et al.
Publicado: (2019) -
Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
por: Brandes, Franziska, et al.
Publicado: (2015) -
INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models
por: Moran-Jones, Kim, et al.
Publicado: (2015) -
Erratum to A phase II study of the efficacy and safety of the MET
inhibitor capmatinib (INC280) in patients with advanced hepatocellular
carcinoma
Publicado: (2020)